Prima awarded patent for CVac

|About: Prima BioMed Ltd (PBMD)|By:, SA News Editor

The USPTO issues patent No. 8,771,701 entitled "Compositions for immunotherapy and uses thereof" protecting Prima BioMed's (PBMD +9.8%) CVac technology. CVac is a personalized immunotherapy. The patent's term extends to August 2022.

The patent covers the method of composition and the method of use of CVac, which uses the patient's own dendritic cells that are reinjected back into the patient to generate a cytotoxic T cell response against the mucin 1 antigen.